Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) EV/FCF
As of 5 November 2026, Sanofi (SNY) trades at a EV/FCF of 7.5×. Over the past ten years it has ranged from 4.7× (April 2024) to 15.9× (April 2015); the current reading is higher than 42% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 7.0× | 10.93% |
| FY2024 | 6.3× | 22.75% |
| FY2023 | 5.2× | 2.87% |
| FY2022 | 5.0× | (33.32%) |
| FY2021 | 7.5× | (14.59%) |
| FY2020 | 8.8× | 4.87% |
| FY2019 | 8.4× | 22.61% |
| FY2018 | 6.8× | 2.36% |
| FY2017 | 6.7× | (18.81%) |
| FY2016 | 8.2× | (16.27%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 6.7× | (18.32%) |
| Jun 2026 | 8.2× | 17.23% |
| Mar 2026 | 7.0× | 0.17% |
| Dec 2025 | 7.0× | (51.41%) |
| 39 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi | 7.5× |
| GSK GSK PLC Sponsored ADR compare | 14.6× |
| GILD Gilead Sciences, Inc. compare | 16.5× |
| BMY Bristol Myers Squibb Company compare | 17.2× |
| PFE Pfizer Inc. compare | 19.9× |
| NVS Novartis AG compare | 24.4× |
| NVO Novo Nordisk A/S compare | 25.4× |
| AMGN Amgen Inc. compare | 31.8× |
| AZN AstraZeneca PLC compare | 49.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement